Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology

被引:88
|
作者
D'Alto, Michele [1 ]
Romeo, Emanuele [1 ]
Argiento, Paola [1 ]
Sarubbi, Berardo [1 ]
Santoro, Giuseppe [1 ]
Grimaldi, Nicola [1 ]
Correra, Anna [1 ]
Scognamiglio, Giancarlo [1 ]
Russo, Maria Giovanna [1 ]
Calabro, Raffaele [1 ]
机构
[1] Univ Naples 2, Dept Cardiol, Monaldi Hosp, Naples, Italy
关键词
Pulmonary arterial hypertension; Congenital heart disease; Association therapy; IMPROVES FUNCTIONAL-CAPACITY; ORAL SILDENAFIL; COMBINATION THERAPY; INHALED ILOPROST; CLINICAL-TRIAL; ADULT PATIENTS; 6-MINUTE WALK; OPEN-LABEL; EFFICACY; TOLERABILITY;
D O I
10.1016/j.ijcard.2010.10.051
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The aim of the present study was to evaluate the safety, tolerability, clinical and haemodynamic impact of add-on sildenafil in patients with congenital heart disease (CHD)-related pulmonary arterial hypertension (PAH) and Eisenmenger physiology after failure of oral bosentan therapy. Methods: Thirty-two patients with CHD-related PAH (14 male, mean age 37.1 +/- 13.7 years) treated with oral bosentan underwent right heart catheterization (RHC) for clinical worsening. After RHC, all patients received oral sildenafil 20 mg thrice daily in addition to bosentan. Clinical status, resting transcutaneous oxygen saturation (SpO(2)), 6-minute walk test (6MWT), serology and RHC were assessed at baseline (before add-on sildenafil) and after 6 months of combination therapy. Results: Twelve patients had ventricular septal defect, 8 atrio-ventricular canal, 6 single ventricle, and 6 atrial septal defect. Twenty-eight/32 had Eisenmenger physiology and 4 (all with atrial septal defect) did not. All patients well tolerated combination therapy. After 6 months of therapy, an improvement in clinical status (WHO functional class 2.1 +/- 0.4 vs 2.9 +/- 0.3; P=0.042), 6-minute walk distance (360 +/- 51 vs 293 +/- 68 m; P=0.005), SpO(2) at the end of the 6MWT (72 +/- 10 vs 63 +/- 15%; P=0.047), Borg score (2.9 +/- 1.5 vs 4.4 +/- 2.3; P=0.036), serology (pro-brain natriuretic peptide 303 +/- 366 vs 760 +/- 943 pg/ml; P=0.008) and haemodynamics (pulmonary blood flow 3.4 +/- 1.0 vs 3.1 +/- 1.2 l/min/m(2), P=0.002; pulmonary vascular resistances index 19 +/- 9 vs 24 +/- 16 WU/m(2), P=0.003) was observed. Conclusions: Addition of sildenafil in adult patients with CHD-related PAH and Eisenmenger syndrome after oral bosentan therapy failure is safe and well tolerated at 6-month follow-up, resulting in a significant improvement in clinical status, effort SpO(2), exercise tolerance and haemodynamics. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:378 / 382
页数:5
相关论文
共 50 条
  • [31] Consecutive use of sildenafil and bosentan for the treatment of pulmonary arterial hypertension associated with collagen vascular disease: sildenafil as reliever and bosentan as controller
    Kamata, Y.
    Iwamoto, M.
    Minota, S.
    LUPUS, 2007, 16 (11) : 901 - 903
  • [32] Pulmonary Arterial Hypertension Associated with Congenital Heart Disease
    Zuckerman W.A.
    Krishnan U.
    Rosenzweig E.B.
    Current Pediatrics Reports, 2013, 1 (2) : 92 - 101
  • [33] Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease
    Alain Fraisse
    Ghazwan Butrous
    Mary B. Taylor
    Michael Oakes
    Maria Dilleen
    David L. Wessel
    Intensive Care Medicine, 2011, 37 : 502 - 509
  • [34] Pulmonary arterial hypertension associated with congenital heart disease
    D'Alto, Michele
    Mahadevan, Vaikom S.
    EUROPEAN RESPIRATORY REVIEW, 2012, 21 (126) : 328 - 337
  • [35] Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease
    Fraisse, Alain
    Butrous, Ghazwan
    Taylor, Mary B.
    Oakes, Michael
    Dilleen, Maria
    Wessel, David L.
    INTENSIVE CARE MEDICINE, 2011, 37 (03) : 502 - 509
  • [36] Prolonged beneficial effect of bosentan treatment and 4-year survival rates in adult patients with pulmonary arterial hypertension associated with congenital heart disease
    Vis, Jeroen C.
    Duffels, Marielle G.
    Mulder, Pepijn
    de Bruin-Bon, Rianne H. A. C. M.
    Bouma, Berto J.
    Berger, Rolf M. F.
    Hoendermis, Elke S.
    van Dijk, Arie P. J.
    Mulder, Barbara J. M.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 164 (01) : 64 - 69
  • [37] Pulmonary arterial hypertension associated with congenital heart disease
    Kulik, Tom
    Mullen, Mary
    Adatia, Ian
    PROGRESS IN PEDIATRIC CARDIOLOGY, 2009, 27 (1-2) : 25 - 33
  • [38] Pulmonary arterial hypertension in adults with congenital heart disease
    Bouzas, B
    Gatzoulis, MA
    REVISTA ESPANOLA DE CARDIOLOGIA, 2005, 58 (05): : 465 - 469
  • [39] Long-term results of treatment with bosentan in adult Eisenmenger's syndrome patients with Down's syndrome related to congenital heart disease
    Crepaz, Roberto
    Romeo, Cristina
    Montanaro, Donato
    De Santis, Stefano
    BMC CARDIOVASCULAR DISORDERS, 2013, 13
  • [40] Pulmonary arterial hypertension in congenital heart disease
    Ferrero, Paolo
    Krishnathasan, Kaushiga
    Constantine, Andrew
    Chessa, Massimo
    Dimopoulos, Konstantinos
    HEART, 2024, 110 (18) : 1145 - 1152